Nanoparticle formulations for DNA-targeted radiotherapy and imaging: combinations with chromatin-modifying compounds. This project will develop a new approach for treating and imaging cancer using nanoparticles which target specific cells for cancer therapy and diagnostic imaging. The nanoparticles will be combined with compounds that alter the architecture of DNA to make therapy more effective and to improve the safety of imaging.
Rapid detection of rare-event cells by strong UP-conversion
encoded nano-radiators (SUPER Dots): finding a needle in a haystack. Current diagnostic tests are not sensitive enough to detect cancer in its very early stages or early recurrence following treatment. The new technologies developed by this project will be able to find single cancer cells in blood and urine samples heralding a new era in medical diagnostics.
Image-guided skin microbiopsy technology development. There is a need for targeted biopsies in dermatology. This novel technology enables minimally invasive biopsies to be taken from suspicious skin lesions by integrating micromedical and imaging devices.
Microscale microRNA Detection and Delivery for Effective Point-of-Care Cancer Screening and Therapeutics. MicroRNAs are short RNA molecules that play a critical regulatory role in gene expression. Recently discovered in 1993, microRNA research has since received considerable attention and is regarded as an emerging revolutionary frontier in medicine given its therapeutic ability to ‘turn off’ certain genes that lead to various diseases. Additionally, microRNA expression signatures are a strong b ....Microscale microRNA Detection and Delivery for Effective Point-of-Care Cancer Screening and Therapeutics. MicroRNAs are short RNA molecules that play a critical regulatory role in gene expression. Recently discovered in 1993, microRNA research has since received considerable attention and is regarded as an emerging revolutionary frontier in medicine given its therapeutic ability to ‘turn off’ certain genes that lead to various diseases. Additionally, microRNA expression signatures are a strong biomarker for many diseases such as cancer. This project will advance the chip-scale acoustic microcentrifugation and nebulisation technology we recently pioneered to overcome the significant hurdles currently faced in microRNA detection and delivery with the aim of developing prototype portable microdevices for early stage cancer screening and therapy.Read moreRead less
Discovery Early Career Researcher Award - Grant ID: DE140101788
Funder
Australian Research Council
Funding Amount
$358,920.00
Summary
Structural Analysis of Biomolecular Complexes at Membrane Interfaces Important to Health and Disease. This project will study structural aspects of key biomolecular complexes at membrane interfaces that are involved with apoptosis (programmed cell death). Malfunctions in apoptosis have been implicated in many aliments including age-related diseases and cancers. Understanding of the molecular and structural aspects of key complexes can pave the way to novel therapies. The approach that will be us ....Structural Analysis of Biomolecular Complexes at Membrane Interfaces Important to Health and Disease. This project will study structural aspects of key biomolecular complexes at membrane interfaces that are involved with apoptosis (programmed cell death). Malfunctions in apoptosis have been implicated in many aliments including age-related diseases and cancers. Understanding of the molecular and structural aspects of key complexes can pave the way to novel therapies. The approach that will be used is to design new biomimetic outer mitochondrial membranes and use these to study the structure and binding of proteins involved with apoptosis. By studying simple models of complex systems, this project promises to yield detailed information on important biomolecular complexes where structural detail is currently lacking. Read moreRead less
Proteomic study of urine to discover novel biomarkers for human prostate cancer. The purpose of this project is to identify novel markers in the urine of patients with prostate cancer. These biomarkers may ultimately prove useful in the development of novel diagnostic tools for the management of this disease.
Proteomic study of tears to discover novel biomarkers for human breast cancer. The purpose of this project is to identify novel markers in the tears of patients with breast cancer. The results from this study may improve the prognosis of breast cancer patients.
mTOR signalling in serous ovarian cancer. Serous ovarian cancer is the most aggressive and lethal gynaecological cancer in Australian women. Activation of Mammalian Target of Rapamycin (mTOR) is frequently observed and associated with poor prognosis in ovarian cancer patients. However, the mechanisms dysregulating mTOR in the pathogenesis of ovarian cancer are unknown. In preliminary studies, deletion of genes regulating mTOR signalling in up to 60 per cent of human serous ovarian cancer patien ....mTOR signalling in serous ovarian cancer. Serous ovarian cancer is the most aggressive and lethal gynaecological cancer in Australian women. Activation of Mammalian Target of Rapamycin (mTOR) is frequently observed and associated with poor prognosis in ovarian cancer patients. However, the mechanisms dysregulating mTOR in the pathogenesis of ovarian cancer are unknown. In preliminary studies, deletion of genes regulating mTOR signalling in up to 60 per cent of human serous ovarian cancer patients was observed. This project will provide mechanistic details of involvement of mTOR signalling in pathogenesis of the serous ovarian carcinoma, and develop a rationale for targeting mTOR pathway in these patients. Read moreRead less
The critical role of the class III histone deacetylase SIRT2 in stabilizing N-Myc oncoprotein. Cancer is the commonest cause of death from disease in children. Neuroblastoma is the commonest solid tumor in early childhood. This project will investigate the critical roles of SIRT2 protein in increasing the expression of N-Myc oncoprotein and consequently inducing neuroblastoma, and SIRT2 inhibitors as anticancer agents.
Mitochondrially targeted anti-cancer drugs modulate the mitochondrial genome. Successful cancer management requires novel therapeutical approaches. This project will test the effect of a new class of compounds that target mitochondria, the powerhouse of the cells, where they suppress expression of mitochondrial genes. By this mechanism, cancers that are resistant to apoptosis induction can be inhibited.